| 76.06 Delayed Data As of Nov 16 |  +1.22 / +1.63%Today’s Change | 52.83 Today|||52-Week Range 76.25 | +35.17% Year-to-Date |
| Previous close | 74.84 |
| Today’s open | 74.74 |
| Day’s range | 74.55 - 76.25 |
| Volume | 13,725,173 |
| Average volume (3 months) | 9,616,397 |
| Market cap | $197.8B |
| Earnings growth (last year) | -38.03% |
| Earnings growth (this year) | +9.06% |
| Earnings growth (next 5 years) | +8.77% |
| Revenue growth (last year) | +1.23% |
| P/E ratio | 60.8 |
| Price/Sales | 3.87 |
| Price/Book | 5.97 |
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | +0.51 | +0.58% |
| PFEPfizer | +0.30 | +0.69% |
| ABBVAbbVie | +1.39 | +1.54% |
| ABTAbbott Laboratories | +1.31 | +1.85% |
| Next reporting date | February 1, 2019 |
| EPS forecast (this quarter) | $1.05 |
| Annual revenue (last year) | $40.0B |
| Annual profit (last year) | $2.4B |
| Net profit margin | 5.99% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman, President & Chief Executive Officer Kenneth C. Frazier |
CFO & Executive Vice President-Global Services Robert M. Davis |
Corporate headquarters Kenilworth, New Jersey |
